Fondaparinux and acute coronary syndromes: Update on the OASIS 5-6 studies

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 179-187

  Schiele, François ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Acute coronary syndromes; Fondaparinux; Oasis

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NOVO7; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANTICOAGULANT THERAPY; BLEEDING; CATHETER THROMBOSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; EUROPE; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 77950810275     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6099     Document Type: Review

References (33)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guide- lines for the Management of Patients With Unstable Angina/Non-ST- Elevation Myocardial Infarction-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non- ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Car-diovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):652-726.
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.
3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low- molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxa- parin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447-452.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myo-cardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100(15):1593-1601.
5. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477-1488.
6. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfraction- ated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54.
7. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. Nov 23 2006;355(21):2203-2216.
8. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin dur- ing primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
9. Petitou M, Herault JP, Bernat A, et al. Synthesis of thrombin-inhibiting hep- arin mimetics without side effects. Nature. 1999;398(6726):417-422.
10. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345(18):1305-1310.
11. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboem- bolism after hip-fracture surgery. N Engl J Med. 2001 Nov 1;345(18): 1298-1304.
12. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81(2):214-220.
13. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor- Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J. 2001;22(18):1716-1724.
14. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005;111(11):1390-1397.
15. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-1476.
16. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation mycardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519-1530.
17. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-2945.
18. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28(13):1598-1660.
19. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guide-lines(8th Edition). Chest. 2008;133(6 Suppl):670S-707S.
20. Schiele F, Meneveau N, Seronde MF, et al. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. Am Heart J. 2010;159(2):190-198.
21. Mehta SR, Boden WE, Eikelboom JW, et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syn- dromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation. 2008;118(20):2038-2046.
22. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syn- dromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50(18):1742-1751.
23. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):708S-775S.
24. Stief TW. Kallikrein activates prothrombin. Clin Appl Thromb Hemost. 2008;14(1):97-98.
25. Maegdefessel L, Buerke M, Schubert S, et al. Comparison of bivali- rudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. Thromb Haemost. 2008;100(4):693-698.
26. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30(12): 1457-1466.
27. Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non- ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006;48(7):1346-1354.
28. Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet. 2008;371(9624):1559-1561.
29. Bassand JP, Hamm C. Guidelines for anticoagulant use in acute coronary syndromes. Lancet. 2008;372(9638):532-533; author reply 533-534.
30. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology. 2004;9(5-6):317-332.
31. Haverkamp D, Hutten BA, Buller HR, Gallus AS, Lensing AW, Prins MH. The use of specific antidotes as a response to bleeding com- plications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost. 2003;1(1):69-73.
32. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recom- binant factor VIIa to reverse the anticoagulant effect of the pentasac- charide fondaparinux in healthy volunteers. Circulation. 2002;106(20): 2550-2554.
33. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457-2467.